Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protalix Biotherapeutics (NY: PLX )

2.060 -0.030 (-1.44%)
Official Closing Price Updated: 8:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 915,000
Open 2.100
Bid (Size) 2.070 (5)
Ask (Size) 2.090 (39)
Prev. Close 2.090
Today's Range 2.060 - 2.129
52wk Range 1.000 - 3.550
Shares Outstanding 65,414,917
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we see what shares are on rising and falling on Tuesday! 
Via InvestorPlace

Performance

YTD
+50.36%
+50.36%
1 Month
-28.97%
-28.97%
3 Month
+10.16%
+10.16%
6 Month
+85.59%
+85.59%
1 Year
+74.58%
+74.58%

More News

Read More
Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil
Via Benzinga
Why Lucira Health Shares Are Trading Higher By Over 228%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Preview For Protalix BioTherapeutics
Via Benzinga
Looking Into Protalix BioTherapeutics's Return On Capital Employed
Via Benzinga
Protalix BioTherapeutics Well Placed to Advance in 2023
Via Talk Markets
Earnings Scheduled For February 27, 2023
Via Benzinga
Earnings Scheduled For May 16, 2022
Via Benzinga
Protalix PRX-102: Likely Approval Could Be A Game Changer
Via Talk Markets
$12.5 Million Bet On Biodesix? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Via News Direct
Exposures Product Safety
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Via TheNewswire.com
Exposures Product Safety
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Via Benzinga
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
Via TheNewswire.com
Why Protalix Is Back On The Radar?
Via Talk Markets
Protalix Shares Surge After Encouraging Topline Data From Another Fabry Disease Trial
Via Benzinga
Earnings Scheduled For November 14, 2022
Via Benzinga
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
Via News Direct
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
Via Benzinga
10 Most-Searched Tickers On Benzinga Pro In April: Musk Mania, Apple Drops, Several Newcomers Move Up
Via Benzinga
Earnings Scheduled For August 15, 2022
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
Why Protalix BioTherapeutics Stock Is Soaring
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.